The recent arrival of synthetic incretins (gut-derived hormones secreted after eating, which stimulate a decrease in blood glucose) onto the market has led to an explosion in their use, primarily for weight loss and as an adjunct in diabetes control. Fuelled by celebrity endorsements, semaglutide (glucagon-like peptide-1 receptor agonist, sold as Ozempic or Wegovy) became the most prescribed drug in the US in 2023. As a result of widespread use, its effect on ocular health is becoming more defined and is beginning to be discussed in the literature.
Sign up to keep reading
Create a free Member account at NZ Optics to read this article and more.
- Read all Member articles
- Full digital magazine archive
- Early access to new articles
